Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects

Eur J Clin Pharmacol. 1993;44(6):575-8. doi: 10.1007/BF02440862.


The plasma pharmacokinetics of pantoprazole have been investigated following single intravenous infusion and single oral administration at a dose of 40 mg to 12 healthy male subjects in a randomised cross-over study. Both treatments were generally well tolerated and no relevant compound-related adverse events were noted. The plasma pharmacokinetics of pantoprazole following intravenous infusion in this group of subjects were characterised by a total plasma clearance of 0.13 l.h-1 x kg-1 and apparent terminal elimination half-life 1.9 h. The apparent volume of distribution estimated at steady state (0.17 was compatible with the localization of a major fraction of the compound in extracellular water. Following oral administration as an enteric-coated tablet formulation, a variable onset of absorption was followed by rapid attainment of maximum plasma concentrations of pantoprazole. Pantoprazole was well absorbed following oral administration; the absolute systemic bioavailability of the compound was estimated as 77% (95% CI, 67 to 89%).

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Adenosine Triphosphatases / antagonists & inhibitors
  • Administration, Oral
  • Adult
  • Benzimidazoles / administration & dosage
  • Benzimidazoles / blood
  • Benzimidazoles / pharmacokinetics*
  • Biological Availability
  • Drug Administration Schedule
  • Half-Life
  • Humans
  • Infusions, Intravenous
  • Male
  • Metabolic Clearance Rate
  • Omeprazole / analogs & derivatives
  • Pantoprazole
  • Sulfoxides / administration & dosage
  • Sulfoxides / blood
  • Sulfoxides / pharmacokinetics*
  • Tablets, Enteric-Coated


  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Benzimidazoles
  • Sulfoxides
  • Tablets, Enteric-Coated
  • Pantoprazole
  • Adenosine Triphosphatases
  • Omeprazole